Clinical Trials Logo

Clinical Trial Summary

Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.


Clinical Trial Description

This observational study will be performed at healthcare facilities treating pediatric psoriasis patients. The study population will consist of a representative group of pediatric patients with moderate-to-severe plaque psoriasis for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 16 weeks Retrospective data collection is planned at patients' inclusion. Prospective data collection will continue during follow-up routine visits until secukinumab discontinuation or maximum duration of follow-up for 104 weeks after index date. ;


Study Design


Related Conditions & MeSH terms

  • Moderate-to-severe Plaque Psoriasis
  • Psoriasis

NCT number NCT06142357
Study type Observational
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Status Recruiting
Phase
Start date December 29, 2023
Completion date July 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT05787236 - A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Active, not recruiting NCT04612699 - A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis Phase 2
Not yet recruiting NCT06258668 - Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Completed NCT06182384 - A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices Phase 1
Recruiting NCT03710681 - A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis Phase 1
Not yet recruiting NCT04839016 - Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis Phase 3